



Xellia Pharmaceuticals recruiting additional >100 employees to expand workforce at its Cleveland, Ohio manufacturing site

Cleveland site to manufacture critical medicines for the US market

Copenhagen, Denmark, 12 May 2020 - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has announced that it is recruiting an additional >100 employees for its Cleveland site, located in Bedford, Ohio.

To date, Xellia has built up a fully trained team with more than 230 employees at the facility. As Xellia ramps up on operations at the site through 2020, onboarding of 100+ additional employees is planned across a range of departments, including manufacturing, supply chain, distribution, quality, engineering, people & organization and finance.

Further expansion of the Cleveland team is expected through 2021 onwards in line with Xellia's long-term strategy for growth at the site, providing more opportunities for the Bedford community in the future.

Carl-Åke Carlsson, Xellia's CEO said:

"We believe strongly that our people make us what we are at Xellia Pharmaceuticals. We thrive on a spirit of innovation, excellence and teamwork, and seek to build talented teams that reflect this culture.

"At a time when a global coronavirus pandemic has brought supply chain disruption for drug products worldwide, maintaining a robust US supply of our vital anti-infective medicines has never been more important. If you want to join a highly skilled and motivated team in leading the fight against infections, then please take a look at our current opportunities at our Cleveland, Ohio site."

All open positions at the Cleveland site are posted on Xellia's career page (<https://career5.successfactors.eu/career?company=xelliapharma>). The hiring team will be conducting virtual interviews and welcoming new employees in accordance with government recommendations with regards to coronavirus risk and employee health and safety.

For more information on recruitment, please visit the Company's career page at <https://career5.successfactors.eu/career?company=xelliapharma>.

- Ends -

For more information, please contact:

Xellia Pharmaceuticals

Craig Boyd, President, Xellia North America
Tel: +1 312-810-0045
Email: Craig.Boyd@xellia.com

Instinctif Partners (International media relations)

Melanie Toyne-Sewell / Siobhan Sanford
Tel: +44 (0) 7890 022 814 / +44 (0) 7534 247 411
Email: xellia@instinctif.com

Kalaheo Consulting (US media relations)

Mike Gaynes
Tel: +1 650-728-0227
Email: mikegaynes@gmail.com

About Xellia Pharmaceuticals

Xellia Pharmaceuticals (“Xellia”) is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.

With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Continuing the Company’s evolution, Xellia is generating an innovative pipeline of value-added anti-infective medicines intended to enhance patient care, providing convenience and ease of use for healthcare professionals.

Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,700 people.

Further information about Xellia can be found at: www.xellia.com.